Alcohol Use Disorder Treatment Market Size, Share, Opportunities, And Trends By Type (Alcohol Abuse, Alcoholism (Alcohol Dependence)), By Treatment (Medication, Behavioural Therapy), And Geography - Forecasts From 2019 To 2024

Published:  Mar 2020 Report Code: KSI061612285 Pages: 111
The alcohol use disorder treatment market is estimated to grow by US$6.750 billion in 2018. The growing demand for the alcohol use disorder treatment is mainly attributed to the prevalence of this disease worldwide, with the high prevalence reported in Eastern European countries, parts of South East Asia and selected countries in Americas. According to the estimates by the Institute of Medicine, in 1996 the prevalence of Fetal Alcohol Syndrome (FAS) in the United States was between 0.5 and 3.0 cases per 1,000. As per the recent reports from the specific U.S. sites, the prevalence of FAS was found to be 2 to 7 cases per 1,000, and the prevalence of Fetal Alcohol Spectrum Disorders (FASD) was estimated to be as high as 20 to 50 cases per 1,000 (Source: National Institutes of Health). Furthermore, the rising number of deaths occurring due to alcohol-related liver disease is driving the market growth during the forecast period.
 
Major industry players profiled as part of the report are Teva Pharmaceuticals USA, Inc., Adial Pharmaceuticals, Alkermes, ADDEX THERAPEUTICS, Kinnov Therapeutics, OPIANT PHARMACEUTICALS, INC, Ethypharm, and MONTISERA LTD.
 
Segmentation
The alcohol use disorder treatment market has been analyzed through following segments:
 
By Type
Alcohol Abuse
Alcoholism (Alcohol dependence)
 
By Treatment
Medication
Behavioural Therapy
 
By Geography
North America
USA
Canada
Mexico
 
South America
Brazil
Argentina
Others
 
Europe
Germany
France
United Kingdom
Spain
Others
 
Middle East and Africa
Saudi Arabia
Israel
Others
 
Asia Pacific
China
Japan
South Korea
India
Others
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY 
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Overview and Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Prevalence
4.5.1. By age group
4.5.2. By gender
4.5.3. By region
4.6. Product Pipeline
4.7. Innovations
5. ALCOHOL USE DISORDER TREATMENT MARKET BY TYPE
5.1. Alcohol Abuse
5.2. Alcoholism (Alcohol dependence)
6. ALCOHOL USE DISORDER TREATMENT MARKET BY TREATMENT
6.1. Medication
6.2. Behavioural Therapy
7. ALCOHOL USE DISORDER TREATMENT MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1.  Competitive Benchmarking and Analysis
8.2.  Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Teva Pharmaceuticals USA, Inc.
9.2. Adial Pharmaceuticals
9.3. Alkermes
9.4. ADDEX THERAPEUTICS
9.5. Kinnov Therapeutics
9.6. OPIANT PHARMACEUTICALS, INC
9.7. Ethypharm
9.8. MONTISERA LTD
LIST OF FIGURES
LIST OF TABLES
Teva Pharmaceuticals USA, Inc.
Adial Pharmaceuticals
Alkermes
ADDEX THERAPEUTICS
Kinnov Therapeutics
OPIANT PHARMACEUTICALS, INC
Ethypharm
MONTISERA LTD

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us